Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection
will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an
apheresis from a compatible donor.
Safety and immunoreconstitution parameters in blood samples will be assessed up to +60 days
after the treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Banc de Sang i Teixits
Collaborators:
Hospital Universitario La Fe Vall d'Hebron Institute of Oncology